23 research outputs found
#ALLBlackLivesMatter: Black Politics, Society, and Intersectionality
This session will allow students to examine and discuss the portrayal of the LGBT community in society such as through media or politics compared to the real every day LGBT community experiences. In addition, the session will engage students in dialogue on reclaiming their identity and owning who they are through an interactive group activity. This session will provide an opportunity for students to hear the experiences, ideas, and feedback of individuals who have a different sexual identity than their own
The LHS 1678 system : two earth-sized transiting planets and an astrometric companion orbiting an M dwarf near the convective boundary at 20 pc
Funding: The MEarth Team gratefully acknowledges funding from the David and Lucile Packard Fellowship for Science and Engineering (awarded to D.C.). This material is based upon work supported by the National Science Foundation under grants AST-0807690, AST-1109468, AST-1004488 (Alan T. Waterman Award), and AST-1616624, and upon work supported by the National Aeronautics and Space Administration under Grant No. 80NSSC18K0476 issued through the XRP Program. This work is made possible by a grant from the John Templeton Foundation. N. A.-D. acknowledges the support of FONDECYT project 3180063. TD acknowledges support from MIT’s Kavli Institute as a Kavli postdoctoral fellow. KH acknowledges support from STFC grant ST/R000824/1. E.A.G. thanks the LSSTC Data Science Fellowship Program, which is funded by LSSTC, NSF Cybertraining Grant #1829740, the Brinson Foundation, and the Moore Foundation; The material is based upon work supported by NASA under award number 80GSFC21M0002. This work was supported by the lead author’s appointment to the NASA Postdoctoral Program at the Goddard Space Flight Center, administered by Universities Space Research Association under contract with NASAWe present the Transiting Exoplanet Survey Satellite (TESS) discovery of the LHS 1678 (TOI-696) exoplanet system, comprised of two approximately Earth-sized transiting planets and a likely astrometric brown dwarf orbiting a bright (VJ = 12.5, Ks = 8.3) M2 dwarf at 19.9 pc. The two TESS-detected planets are of radius 0.70 ± 0.04 R⊕ and 0.98 ± 0.06 R⊕ in 0.86 day and 3.69 day orbits, respectively. Both planets are validated and characterized via ground-based follow-up observations. High Accuracy Radial Velocity Planet Searcher RV monitoring yields 97.7 percentile mass upper limits of 0.35 M⊕ and 1.4 M⊕ for planets b and c, respectively. The astrometric companion detected by the Cerro Tololo Inter-American Observatory/Small and Moderate Aperture Telescope System 0.9 m has an orbital period on the order of decades and is undetected by other means. Additional ground-based observations constrain the companion to being a high-mass brown dwarf or smaller. Each planet is of unique interest; the inner planet has an ultra-short period, and the outer planet is in the Venus zone. Both are promising targets for atmospheric characterization with the James Webb Space Telescope and mass measurements via extreme-precision radial velocity. A third planet candidate of radius 0.9 ± 0.1 R⊕ in a 4.97 day orbit is also identified in multicycle TESS data for validation in future work. The host star is associated with an observed gap in the lower main sequence of the Hertzsprung–Russell diagram. This gap is tied to the transition from partially to fully convective interiors in M dwarfs, and the effect of the associated stellar astrophysics on exoplanet evolution is currently unknown. The culmination of these system properties makes LHS 1678 a unique, compelling playground for comparative exoplanet science and understanding the formation and evolution of small, short-period exoplanets orbiting low-mass stars.Publisher PDFPeer reviewe
The L 98-59 System: Three Transiting, Terrestrial-size Planets Orbiting a Nearby M Dwarf
We report the Transiting Exoplanet Survey Satellite (TESS) discovery of three terrestrial-size planets transiting L 98-59 (TOI-175, TIC 307210830)—a bright M dwarf at a distance of 10.6 pc. Using the Gaia-measured distance and broadband photometry, we find that the host star is an M3 dwarf. Combined with the TESS transits from three sectors, the corresponding stellar parameters yield planet radii ranging from 0.8 R ⊕ to 1.6 R ⊕. All three planets have short orbital periods, ranging from 2.25 to 7.45 days with the outer pair just wide of a 2:1 period resonance. Diagnostic tests produced by the TESS Data Validation Report and the vetting package DAVE rule out common false-positive sources. These analyses, along with dedicated follow-up and the multiplicity of the system, lend confidence that the observed signals are caused by planets transiting L 98-59 and are not associated with other sources in the field. The L 98-59 system is interesting for a number of reasons: the host star is bright (V = 11.7 mag, K = 7.1 mag) and the planets are prime targets for further follow-up observations including precision radial-velocity mass measurements and future transit spectroscopy with the James Webb Space Telescope; the near-resonant configuration makes the system a laboratory to study planetary system dynamical evolution; and three planets of relatively similar size in the same system present an opportunity to study terrestrial planets where other variables (age, metallicity, etc.) can be held constant. L 98-59 will be observed in four more TESS sectors, which will provide a wealth of information on the three currently known planets and have the potential to reveal additional planets in the system
The LHS 1678 System: Two Earth-sized Transiting Planets and an Astrometric Companion Orbiting an M Dwarf Near the Convective Boundary at 20 pc
We present the Transiting Exoplanet Survey Satellite (TESS) discovery of the LHS 1678 (TOI-696) exoplanet system, comprised of two approximately Earth-sized transiting planets and a likely astrometric brown dwarf orbiting a bright (V J = 12.5, K s = 8.3) M2 dwarf at 19.9 pc. The two TESS-detected planets are of radius 0.70 ± 0.04 R ⊕ and 0.98 ± 0.06 R ⊕ in 0.86 day and 3.69 day orbits, respectively. Both planets are validated and characterized via ground-based follow-up observations. High Accuracy Radial Velocity Planet Searcher RV monitoring yields 97.7 percentile mass upper limits of 0.35 M ⊕ and 1.4 M ⊕ for planets b and c, respectively. The astrometric companion detected by the Cerro Tololo Inter-American Observatory/Small and Moderate Aperture Telescope System 0.9 m has an orbital period on the order of decades and is undetected by other means. Additional ground-based observations constrain the companion to being a high-mass brown dwarf or smaller. Each planet is of unique interest; the inner planet has an ultra-short period, and the outer planet is in the Venus zone. Both are promising targets for atmospheric characterization with the James Webb Space Telescope and mass measurements via extreme-precision radial velocity. A third planet candidate of radius 0.9 ± 0.1 R ⊕ in a 4.97 day orbit is also identified in multicycle TESS data for validation in future work. The host star is associated with an observed gap in the lower main sequence of the Hertzsprung-Russell diagram. This gap is tied to the transition from partially to fully convective interiors in M dwarfs, and the effect of the associated stellar astrophysics on exoplanet evolution is currently unknown. The culmination of these system properties makes LHS 1678 a unique, compelling playground for comparative exoplanet science and understanding the formation and evolution of small, short-period exoplanets orbiting low-mass stars
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two
Background
The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd.
Methods
We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background.
Results
First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001).
Conclusions
In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival
Neuroprotective Actions of Methylene Blue and Its Derivatives
<div><p>Methylene blue (MB), the first lead chemical structure of phenothiazine and other derivatives, is commonly used in diagnostic procedures and as a treatment for methemoglobinemia. We have previously demonstrated that MB could function as an alternative mitochondrial electron transfer carrier, enhance cellular oxygen consumption, and provide protection <em>in vitro</em> and in rodent models of Parkinson’s disease and stroke. In the present study, we investigated the structure-activity relationships of MB <em>in vitro</em> using MB and six structurally related compounds. MB reduces mitochondrial superoxide production via alternative electron transfer that bypasses mitochondrial complexes I-III. MB mitigates reactive free radical production and provides neuroprotection in HT-22 cells against glutamate, IAA and rotenone toxicity. Distinctly, MB provides no protection against direct oxidative stress induced by glucose oxidase. Substitution of a side chain at MB’s 10-nitrogen rendered a 1000-fold reduction of the protective potency against glutamate neurototoxicity. Compounds without side chains at positions 3 and 7, chlorophenothiazine and phenothiazine, have distinct redox potentials compared to MB and are incapable of enhancing mitochondrial electron transfer, while obtaining direct antioxidant actions against glutamate, IAA, and rotenone insults. Chlorophenothiazine exhibited direct antioxidant actions in mitochondria lysate assay compared to MB, which required reduction by NADH and mitochondria. MB increased complex IV expression and activity, while 2-chlorphenothiazine had no effect. Our study indicated that MB could attenuate superoxide production by functioning as an alternative mitochondrial electron transfer carrier and as a regenerable anti-oxidant in mitochondria.</p> </div
Redox potential of the MB related compounds.
<p>Redox potential of the MB related compounds.</p
Dose response curves of MB and derivatives in the HT-22 glutamate model.
<p>(A) Dose response curves of MB and derivative against glutamate-induced neurotoxicity measured by Calcein AM; (B) Dose response curves of MB and derivatives against glutamate-induced cellular ROS production measured by DCF assay; (C) Dose response curves of MB and derivatives against mitochondria membrane potential depolarization induced by glutamate measured by NAO/TMRE FRET assay; (D) Correlation of cellular ROS production and cell viability, Pearson coefficient  = 0.8690, p  = 0.00111; (E) Correlation of mitochondria membrane potential and cell viability, Pearson coefficient  = 0.9456, p  = 0.0013; (F) Correlation of cellular ROS production and mitochondria membrane potential, Pearson coefficient  = 0.7902, p  = 0.0345.</p
Effects of the MB and its derivatives on extracellular acidification rate (ECAR).
<p>(A) ECAR recording at baseline and subsequent addition of MB or its derivatives, oligomycin, FCCP, and rotenone. The initial 35 minutes establishes a baseline reading, followed by addition of drug at a concentration of 10 µM. Three subsequent injections followed consisting of 1 µg/ml oligomycin (complex V inhibitor), 300 nM FCCP (proton gradient uncoupler), and 100 nM rotenone (complex I inhibitor). After each injection, 4 time points were recorded with about 35 minutes between injections. (B) MB and TB decreased ECAR as compared to the vehicle control. 2-Chlorophenothiazine and chlorpromazine had no effect as compared to the control. NR, had no effect to vehicle on average, although a spike in ECAR values was observed after NR injection. (C) Oligomycin increased ECAR under all experimental conditions and was significantly reduced by MB, TB, and NR. (D) Injection of FCCP results in maximum cellular OCR with little effect on ECAR; MB, NR, and TB significantly decreased ECAR as compared to the vehicle control. (D) Rotenone inhibits complex I and decreases OCR without change in ECAR. MB, NR and TB caused ECAR to remain significantly less as compared to the vehicle control. * p<0.05 compared to control group.</p
Different action of MB and derivatives as antioxidants.
<p>Four compounds were assayed in the presence or absence of mitochondria lysate and 165 µM NADH to determine their effectiveness in mitigating H<sub>2</sub>O<sub>2</sub> (500 µM) induced DCF oxidation. (A) In the presence of mitochondria lysate and NADH, MB significantly reduced DCF fluorescence at 100 nM, 1 µM and 10 µM. At the same concentrations (100 nM, 1 µM, and 10 µM) in the absence of mitochondria and NADH, MB increased DCF fluorescence. (B) In the presence of mitochondria and NADH, NR decreased DCF fluorescence at a concentration of 1 µM and increased DCF fluorescence at a concentration of 10 µM. NR significantly increased DCF fluorescence at concentrations of 100 nM, 1 µM, and 10 µM in the absence of mitochondria lysate and NADH. (C) 2-Chlorophenothiazine significantly reduced DCF fluorescence at concentrations of 100 and 1 µM in both the presence and absence of mitochondria lysate and NADH. At a concentration of 10 µM, in the presence of mitochondria lysate and NADH, 2-chlorophenothiazine reduced DCF fluorescence; however, in the absence of mitochondria lysate and NADH, 2-chlorophenothiazine increased DCF fluorescence at 10 µM. (D) Chlorpromazine significantly increased DCF fluorescence at concentrations of 100 nM, 1 µM, and 10 µM in both the presence and absence of mitochondria lysate and NADH. * p<0.05 compared to respective H<sub>2</sub>O<sub>2</sub> control group.</p